Expert Interview
Discussing the recent data presented on Arvinas ARV-471; a novel, potent, orally bioavailable PROTAC protein degrader that selectively targets the ER in BREAST CANCER
Ticker(s): ARVNInstituition: Bay Hematology/CHG
- Board certified in Internal medicine and Oncology
- Interests include Leukemia, Non-Hodgkin's Lymphoma, Multiple Myeloma, and Malignant Neoplasm of Female Breast
- Manages 60-80 Breast Cancer patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
